Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
ID: 356614Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356614

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-013.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Discovery and Development of Natural Products for Cancer Interception and Prevention" under the cooperative agreement mechanism. This initiative aims to support innovative projects that focus on the discovery and development of novel natural products that are safe, nontoxic, and effective in intercepting or preventing cancer, with a structured approach divided into two phases: the UG3 phase for initial target selection and assay validation, followed by the UH3 phase for large-scale evaluations and pharmacokinetic assessments. The total funding available for this program is $4.5 million over the fiscal years 2024 to 2026, with a deadline for applications set for June 14, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-CA-25-013.html
    The National Cancer Institute (NCI) of the Department of Health and Human Services seeks applications through the Discovery and Development of Natural Products for Cancer Interception and Prevention initiative (Funding Opportunity Number RFA-CA-25-013) to support innovative projects focusing on natural products that can effectively intercept or prevent cancer. This funding opportunity consists of two phases: a three-year UG3 phase and a potential two-year UH3 phase, contingent upon meeting defined milestones. The UG3 phase involves the initial steps of target selection, assay development, and validation, while the UH3 phase transitions to large-scale evaluations and pharmacokinetic assessments. Targeted natural products are sourced from the NCI's extensive library of pre-fractionated natural products. Applicants are encouraged to apply novel high-throughput screening strategies and develop predictive models for clinical efficacy. The total budget for the program is $4.5 million over the fiscal years 2024 to 2026, allowing for up to 12 awards. Only applications that do not propose clinical trials will be accepted. The deadline for applications is June 14, 2025, and substantial involvement by NIH staff is anticipated throughout the project. This initiative aims to harness the unique characteristics of natural products to advance cancer prevention research significantly.
    Similar Opportunities
    Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the Discovery and Development of Natural Products for Cancer Interception and Prevention, specifically through a cooperative agreement mechanism. This initiative aims to support the discovery and development of novel, safe, and effective natural products that target cancer prevention, structured in two phases: the UG3 phase for initial screenings and assay development lasting up to three years, followed by the UH3 phase for full-scale evaluations lasting up to two years. The program emphasizes the importance of high-throughput screening strategies and collaboration with existing NCI natural product libraries, with a total funding allocation of $4.5 million for approximately 12 awards. Interested applicants must submit their proposals by June 13, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Center for Complementary and Integrative Health (NCCIH), invites applications for the NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33), aimed at supporting early-phase clinical trials of natural products such as botanicals and dietary supplements. This funding opportunity encourages research that evaluates the pharmacokinetics, safety, and efficacy of these natural products, with a focus on advancing promising interventions backed by prior scientific evidence. The program is designed to foster innovative clinical research that enhances understanding of the beneficial impacts of natural products on health conditions, while ensuring inclusivity through a Plan for Enhancing Diverse Perspectives (PEDP). Applicants may request up to $350,000 per year, with a project duration of up to six years contingent upon successful milestone completion, and the application deadline is November 13, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pragmatic Trials across the Cancer Control Continuum" (UG3/UH3), aimed at accelerating the development of evidence-based cancer interventions that reflect the diversity of the U.S. population. This initiative seeks applications that propose interventions designed to improve cancer-related outcomes through pragmatic trial designs, with a particular focus on addressing health disparities among underrepresented populations. The funding opportunity allows for a total of up to $500,000 annually for the UG3 phase and $750,000 for the UH3 phase, with applications accepted until November 17, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)," aimed at accelerating the development of evidence-based cancer interventions that address health disparities among diverse populations in the United States. This initiative will support research that tests the impact of cancer-related interventions on outcomes through a pragmatic trial design, structured in two phases: the UG3 phase for preparatory activities and intervention refinement, followed by the UH3 phase for conducting the trial. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and government entities, with funding amounts capped at $500,000 for the UG3 phase and $750,000 for the UH3 phase. Interested parties should note that applications are due by November 17, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at facilitating well-planned clinical trials that enhance cancer prevention, treatment, and survivorship care. This funding opportunity seeks to address critical gaps in trial planning by acquiring essential data for finalizing protocols, including feasibility assessments and stakeholder engagement strategies. The program is particularly significant for improving cancer-related health behaviors and outcomes, with grants available up to $600,000 for trials including pilot studies, over a maximum of three years. Interested applicants, including higher education institutions and nonprofit organizations, must submit their proposals by September 7, 2025, and can direct inquiries to OERWebmaster03@od.nih.gov for further information.
    NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Center for Complementary and Integrative Health (NCCIH), is inviting applications for the "NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)" grant, aimed at advancing research on natural products such as botanicals and dietary supplements. This funding opportunity encourages mid-phase clinical trials that are hypothesis-driven, focusing on determining optimal dosing or identifying patient phenotypes for future efficacy studies, while explicitly excluding trials for cancer treatment. Eligible applicants include a diverse range of organizations, such as historically black colleges, tribal colleges, and community-based organizations, with a funding ceiling of $350,000 and a submission deadline of November 13, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-24-115.html.
    NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Center for Complementary and Integrative Health (NCCIH), has announced the NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33), aimed at supporting early-phase clinical trials of natural products such as botanicals and dietary supplements. This funding opportunity encourages applications that demonstrate a strong scientific basis for further testing, focusing on pharmacokinetics, bioavailability, and measurable effects on target mechanisms rather than just clinical symptoms. The award consists of two phases: the R61 phase provides up to three years of funding for milestone-driven studies, while the R33 phase may extend funding for an additional three years contingent upon achieving R61 milestones. Interested applicants can find more details and submit inquiries via the NIH Grants Information email at grantsinfo@nih.gov, with a total estimated program funding of $350,000 and a closing date for applications set for November 13, 2026.
    NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NCCIH Natural Product Early Phase Clinical Trial Award (R33), aimed at supporting investigator-initiated clinical trials of natural products such as botanicals and dietary supplements. This funding opportunity encourages applications for early phase trials that assess the impact of these products on specific biological targets and their potential clinical outcomes, with a focus on optimizing study designs and dosage. The initiative is crucial for advancing research in complementary and integrative health approaches, ensuring that projects adhere to rigorous scientific standards and include a Plan for Enhancing Diverse Perspectives (PEDP). The total estimated funding for this program is $1,050,000, with applications due by November 13, 2026. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information page at https://grants.nih.gov/grants/guide/pa-files/PAR-25-270.html.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)" aimed at supporting innovative preclinical and early-phase clinical research in cancer diagnosis, treatment, and prevention. This grant, with a funding ceiling of $275,000 over two years, encourages exploratory studies that may involve significant risk but have the potential to lead to breakthroughs in cancer research, particularly for underserved populations. Applications will be evaluated based on their significance, innovation, and rigor, with key deadlines for submission set for January 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)" aimed at supporting mid-phase clinical trials of natural products, including botanicals, dietary supplements, and probiotics, that demonstrate promising preliminary evidence for health benefits. Applicants are required to provide sufficient preliminary data, adhere to FDA regulations, and develop a Plan for Enhancing Diverse Perspectives (PEDP) to foster inclusivity in research, with a focus on determining optimal dosing and patient responsiveness before advancing to larger efficacy trials. This funding opportunity is critical for addressing knowledge gaps in complementary health approaches, particularly in symptom management and health disparities. The estimated total program funding is $350,000, with applications due by November 13, 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.